APHERESIS ENHANCES THE SELECTIVE REMOVAL OF ANTINUCLEAR ANTIBODIES IN SYSTEMIC LUPUS-ERYTHEMATOSUS

被引:6
作者
COLBURN, KK
GUSEWITCH, GA
POOPRASERT, BSS
WEISBART, RH
机构
[1] Department of Medicine, Loma Linda University and Pettis Memorial Veterans Administration Medical Center Loma Linda, 92354, California
[2] Department of Medicine, UCLA-San Fernando Valley Veterans Administration Medical Center, Sepulveda, 91343, California
关键词
APHERESIS; SLE ACTIVITY; ANTI-DNA ANTIBODIES;
D O I
10.1007/BF02030508
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Apheresis suppresses clinical manifestations of lupus and reduces levels of antinuclear antibodies implicated in the pathogenesis of systemic lupus erythematosus (SLE). It is not known, however, if reduced levels of antinuclear antibodies are due to nonspecific removal, or specific mechanisms associated with decreased production, or enhanced clearance from the circulation. In order to distinguish between specific and nonspecific effects of apheresis on antinuclear antibodies in SLE, we compared plasma levels of IgG antibodies to DNA and IgG antibodies to microbial antigens in 13 SLE patients before and after apheresis. Although apheresis lowered plasma levels of IgG (21% mean reduction), there was a disproportionate reduction in IgG antibodies to DNA (42% mean reduction, p < 0.13). In marked contrast, reduction in antibodies to microbial antigens did not exceed those of plasma IgG. A rapid rebound of serum anti-DNA antibodies following apheresis in certain SLE patients suggests that the selective reduction in anti-DNA antibodies is due to enhanced clearance from the circulation rather than decreased production. These results indicate that apheresis enhances selective removal of antinuclear antibodies in some patients with SLE.
引用
收藏
页码:475 / 482
页数:8
相关论文
共 28 条
  • [1] Jones J.V., Clough J.D., Klinenberg J.R., Et al., The role of therapeutic plasmapheresis in the rheumatic diseases, J Lab Clin Med, 97, 5, pp. 589-598, (1981)
  • [2] Rothwell R.S., Davis P., Gordon P.A., Et al., A controlled study of plasma exchange in the treatment of severe rheumatoid arthritis, Arthritis Rheum, 23, 7, pp. 785-90, (1980)
  • [3] Wallace D.J., Goldfinger D., Gatt R., Et al., Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis, Arthritis Rheum, 22, (1979)
  • [4] Wei N., Klippel J.H., Huston D.P., Et al., Randomized trial of plasma exchange in mild systemic lupus erythematosus, Lancet, 1, pp. 17-22, (1983)
  • [5] Dau P.C., Kahaleh M.B., Sagebiel R.W., Plasmapheresis and immunosuppressive drug therapy in scleroderma, Arthritis Rheum, 24, 9, pp. 1128-36, (1981)
  • [6] Jones J.V., Robinson M.F., Parciany R.K., Et al., Therapeutic plasmapheresis in systemic lupus erythematosus, Arthritis Rheum, 24, 9, pp. 1113-1120, (1981)
  • [7] Abdou N.I., Lindsley H.B., Pollock A., Et al., Plasmapheresis in active systemic lupus erythematosus: Effects on clinical, serum and cellular abnormalities, Case Report. Clin Immunol Immunopathol, 19, pp. 44-54, (1981)
  • [8] Fitchen J.J., Cline M.J., Saxon A., Et al., Serum inhibitors of hematopoiesis in a patient with aplastic anemia and systemic lupus erythematosus, Am J Med, 66, pp. 537-42, (1979)
  • [9] Young D.W., Thompson R.A., Mackie P.H., Plasmapheresis in hereditary angioneurotic edema and systemic lupus erythematosus, Arch Intern Med, 140, pp. 127-9, (1980)
  • [10] Parry H.F., Moran C.J., Snaith M.L., Et al., Plasma exchange in systemic lupus erythematosus, Ann Rheum Dis, 40, pp. 224-8, (1981)